SCHEMBL4670176

SCHEMBL4670176

CCCCc1oc2ccccc2c1C(=O)N(CCCC)Cc1ccc2cc(O)ccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.61
EYA3 Q99504 2/20 0.55
TTR P02766 1/20 0.49
NR1H4 Q96RI1 1/20 0.48
SIRT3 Q9NTG7 4/20 0.47
THRA P10827 2/20 0.46
THRB P10828 2/20 0.46
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 2/20 0.45
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM5A P29375 2/20 0.44
KDM7A Q6ZMT4 2/20 0.44
MLNR O43193 1/20 0.44
CACNA1F O60840 1/20 0.44
PHF2 O75151 1/20 0.44
ABCB11 O95342 1/20 0.44
NR3C1 P04150 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673730 0.92 PTPN1 (0.61) PTPN1EYA3TTRNR1H4SIRT3
SCHEMBL4672112 0.89 PTPN1 (0.49) PTPN1EYA3ALDH1A1SMN1; SMN2LMNA
SCHEMBL4673151 0.82 EYA3 (0.52) PTPN1EYA3TTRNR1H4THRB
SCHEMBL4672535 0.79 PTPN1 (0.64) PTPN1EYA3TTRNR1H4SIRT3
SCHEMBL4672606 0.77 CYP2C19 (0.47) PTPN1EYA3ALDH1A1SMN1; SMN2LMNA
SCHEMBL4674317 0.76 NR1H4 (0.49) PTPN1EYA3NR1H4SIRT3THRA
SCHEMBL5413786 0.76 PTPN1 (1.00) PTPN1EYA3TTRNR1H4
SCHEMBL3971979 0.73 TTR (0.54) PTPN1EYA3TTRNR1H4SIRT3
SCHEMBL4672472 0.72 PTPN1 (0.58) PTPN1EYA3TTRNR1H4SIRT3
SCHEMBL1287970 0.72 EYA3 (1.00) PTPN1EYA3TTRNR1H4SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397341-B1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH CORP (US) 2008-08-06 EP disclosed
EP-1397341-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) Wyeth (US) 2004-03-17 EP disclosed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US disclosed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US disclosed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) SERPINC1, F11, SERPINE1 PTPN1 885/4885EYA3 3991/4885TTR 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.